Daniel Aeschlimann

Prof. Daniel Aeschlimann

Cardiff University, Cardiff, UK
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1992 in Journal of Biological Chemistry
Verified
Journal Article
Open access
EHE Hedbom
E Hedbom
PAP Antonsson
P Antonsson
AHA Hjerpe
A Hjerpe
DADaniel Aeschlimann
Daniel Aeschlimann
MPM Paulsson
M Paulsson
DHD Heinegård
D Heinegård

1 March 2010 in The Lancet Neurology
Verified
Journal Article
Closed access
Marios HadjivassiliouMarios Hadjivassiliou
Marios Hadjivassiliou
DSDavid S Sanders
David S Sanders
RGRichard A Grünewald
Richard A Grünewald
NWNicola Woodroofe
Nicola Woodroofe
SBSabrina Boscolo
Sabrina Boscolo
DADaniel Aeschlimann
Daniel Aeschlimann

1 January 2000 in Connective Tissue Research
Verified
Journal Article
Closed access
PDF file
DADaniel Aeschlimann
Daniel Aeschlimann
VTVilmos Thomazy
Vilmos Thomazy
Transglutaminases form a family of proteins that have evolved for specialized functions such as protein crosslinking in haemostasis, semen coagulation, or keratinocyte cornified envelope formation. In contrast to the other members of this protein family, tissue transglutaminase is a multifunctional enzyme apparently involved in very disparate biological processes. By virtue of its reciprocal Ca2+-dependent crosslinking activity or GTP-dependent signal transducing activity, tissue transglutaminase exhibits true multifunctionality at the molecular level. The crosslinking activity can subserve disparate biological phenomena depending on the location of the target proteins. Intracellular activation of tissue transglutaminase can give rise to crosslinked protein envelopes in apoptotic cells, whereas extracellular activation contributes to stabilization of the extracellular matrix and promotes cell-substrate interaction. While tissue transglutaminase synthesis and activation is normally part of a protective cellular response contributing to tissue homeostasis, the enzyme has also been implicated in a number of pathological conditions including fibrosis, artherosclerosis, neurodegenerative diseases, celiac disease, and cancer metastasis. This review discusses the role of transglutaminases in extracellular matrix crosslinking with a focus on the multifunctional enzyme tissue transglutaminase.

28 September 2008 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MHMarios Hadjivassiliou
Marios Hadjivassiliou
PAPascale Aeschlimann
Pascale Aeschlimann
ASAlexander Strigun
Alexander Strigun
DSDavid S. Sanders
David S. Sanders
NWNicola Woodroofe
Nicola Woodroofe
DADaniel Aeschlimann
Daniel Aeschlimann

16 June 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ZSZsuzsa Szondy
Zsuzsa Szondy
ZSZsolt Sarang
Zsolt Sarang
PMPéter Molnár
Péter Molnár
TNTamás Németh
Tamás Németh
MPMauro Piacentini
Mauro Piacentini
LFLászló Fésüs
László Fésüs
Tissue transglutaminase (TGase2) is a protein-crosslinking enzyme known to be associated with thein vivoapoptosis program. Here we report that apoptosis could be induced in TGase2-/-mice; however, the clearance of apoptotic cells was defective during the involution of thymus elicited by dexamethasone, anti-CD3 antibody, or γ-irradiation, and in the liver after induced hyperplasia. The lack of TGase2 prevented the production of active transforming growth factor-β1 in macrophages exposed to apoptotic cells, which is required for the up-regulation of TGase2 in the thymusin vivo, for accelerating deletion of CD4+CD8+ cells and for efficient phagocytosis of apoptotic bodies. The deficiency is associated with the development of splenomegaly, autoantibodies, and immune complex glomerulonephritis in TGase2-/-mice. These findings have broad implications not only for diseases linked to inflammation and autoimmunity but also for understanding the interrelationship between the apoptosis and phagocytosis process.

31 March 2015 in The Cerebellum
Verified
Journal Article
Open access
PDF file
Hiroshi MitomaHiroshi Mitoma
Hiroshi Mitoma
KAKeya Adhikari
Keya Adhikari
DADaniel Aeschlimann
Daniel Aeschlimann
PCPartha Chattopadhyay
Partha Chattopadhyay
MHMarios Hadjivassiliou
Marios Hadjivassiliou
NYNobuhiro Yuki
Nobuhiro Yuki
In the last few years, a lot of publications suggested that disabling cerebellar ataxias may develop through immune-mediated mechanisms. In this consensus paper, we discuss the clinical features of the main described immune-mediated cerebellar ataxias and address their presumed pathogenesis. Immune-mediated cerebellar ataxias include cerebellar ataxia associated with anti-GAD antibodies, the cerebellar type of Hashimoto’s encephalopathy, primary autoimmune cerebellar ataxia, gluten ataxia, Miller Fisher syndrome, ataxia associated with systemic lupus erythematosus, and paraneoplastic cerebellar degeneration. Humoral mechanisms, cell-mediated immunity, inflammation, and vascular injuries contribute to the cerebellar deficits in immune-mediated cerebellar ataxias.